ImmuPharma (LON:IMM) Stock Price Down 11.3% - What's Next?

Key Points

• ImmuPharma plc shares dropped 11.3% on Monday, with trading prices falling to as low as GBX 10.51 ($0.14), signaling investor concerns.
• The company reported a net margin of 3,519.56% but faced challenges with a negative return on equity of 131.41% and is projected to post earnings of -339.0 for the current fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics, notably their lead program, P140 (Lupuzor™), aimed at treating autoimmune diseases such as Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) dropped 11.3% on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.09 ($0.15). Approximately 9,637,198 shares changed hands during mid-day trading, an increase of 13% from the average daily volume of 8,505,251 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Trading Down 10.0%

The firm has a 50 day simple moving average of GBX 4.28 and a two-hundred day simple moving average of GBX 3.27. The company has a market capitalization of £56.23 million, a PE ratio of -1,264.38 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.